Elizabeth Griffiths, MD

Staff Physician, Leukemia Service, Department of Medicine

Roswell Park Cancer Institute

Profile

Areas of Expertise:

Acute lymphoblastic leukemia (ALL)

Acute myeloid leukemia (AML)

Chronic myeloid leukemia (CML)

Hematologic Oncology

Myelodysplastic syndrome (MDS)

Myeloproliferative diseases (MPD)

Research

Research Interests:

Epigenetic changes in leukemia and myelodysplastic syndromes, novel therapeutics for elderly Acute Myeloid Leukemia

Selected Publications:

Peer-Reviewed Publications:

1. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Karp JE, Herman JG, Carraway HE. Epigenetic differences cytogenetically normal vs. abnormal acute myeloid leukemia. Epigenetics 2010;5(7) .

2. Griffiths EA, Gore SD, Herman JG, Hooker CM, Karp JE, Smith BD, McDevitt MA, Mohammad HP, Ye Y, Carraway HE. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter methylation. Leuk Lymphoma in press 2010.

3. Bailey VJ, Keeley BP, Razavi CR, Griffiths E, Carraway HE, Wang TH. DNA methyltaion detection using MS-qFRET, a quantum dot-based nanoassay. Methods. 2010.

4. Bailey VJ, Easwaran H, Zhang Y, Griffiths EA, Belinsky SA, Herman JG, Baylin SB, Carraway HE, and Wang TH. MS-qFRET: A quantum dot-based method for analysis of DNA methylation. Genome Research 2009;19:1455-61.

5. Zhang Y, Bailey V, Puelo CM, Easwarn H, Griffiths EA, Herman JM, Baylin SB, Wang TH. High throughput DNA methylation analysis on a droplet-in-oil PCR array. Lab Chip 2009; 9:1059-64.

6. Peng T, Blakeley J, Cingolani E, Griffiths EA, Grossman SA. Herpes simplex encephalitis in a patient with recurrent pituitary adenoma receiving radiation therapy. Am J Clin Oncol 2007; 30:664-5.

7. Griffiths, EA. The Hippocratic Oath: Searching For an Ideal. N C Med J 2000; 61:136-40.

Review Articles:

1. Griffiths EA and Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008; 45:23-30.

2. El-Shami, K, Griffiths EA and Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. Oncologist 2007; 12:518-23

Editorials:

1. Griffiths EA, Gore SD. MicroRNA: mIR-ly regulators of DNA methyltransferase? Blood 2009;113:6269-70.

2. Griffiths EA and Gore SD. DNA methyltransferase inhibitors: class effect or unique agents? Leuk Lymphoma 2008; 49:650-1.

Background Information

Education and Training:

University of North Carolina School of Medicine, Chapel Hill, NC

Residency:

Johns Hopkins Hospital, Baltimore, MD

Board Certification:

Hematology, American Board of Internal Medicine

Oncology, American Board of Internal Medicine

Internal Medicine, American Board of Internal Medicine

Fellowships:

Sidney Kimmel Comprehensive Cancer Center

Johns Hopkins Hospital, Baltimore, MD

Publications

Publications:

Griffiths EA, Herman JG, Ye Y, Mohammad HP, Smith BD, Karp JE, McDevitt MA, Hooker C, Gore SD, Carraway HE. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leukemia and lymphoma 2010; 51(9):1711-1719
Bailey VJ , Keeley BP , Razavi CR , Griffiths E , Carraway HE , Wang T-H. DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay. Methods (San Diego, Calif.) 2010; 52(3):237-241
Griffiths EA , Gore SD , Hooker CM , Mohammad HP , McDevitt MA , Smith BD , Karp JE , Herman JG , Carraway HE. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010; 5(7):590-600
Lee HJ, Trump D, Johnson CS, Wang ES, Thompson JE, Griffiths EA, Vigil CE, Barcos M, Block A, Sait S, Ford LA, Wilding G, Wei T, Muindi J, Wetzler M. Subnormal vitamin D levels are associated with adverse outcome in newly-diagnosed similarly-treated adult acute myeloid leukemia (AML) patients. Blood 2010; 116(21):Abstract #1041
Vigil CE, Griffiths EA, Wang ES, Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood reviews 2011; 25(3):139-146
Lee HJ, Wright KM, Kandeel E, Tan W, Wilding GE, Ford LA, Sait SN, Block AMW, Barcos MP, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6592
Griffiths EA, Karpf AR, Odunsi K, James SR, Beck AF, Wetzler M, Ford LA. Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo. Blood 2011; 118(21):1049
Vigil CE, Griffiths EA, Thompson JE, Tan W, Greene J, Ford LA, Wang ES, Wetzler M. A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6602
Sardesai SD, Tan W, Ford LA, Deeb G, Block AMW, Sait SNJ, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6565
Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Advances in experimental medicine and biology 2013; 754 :253-283

Referral

Email:

Elizabeth.Griffiths@RoswellPark.org

Fax:

716-845-1322